SOPHiA GENETICS (NASDAQ:SOPH) & Hims & Hers Health (NYSE:HIMS) Financial Comparison

Hims & Hers Health (NYSE:HIMS) and SOPHiA GENETICS (NASDAQ:SOPH) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Valuation & Earnings

This table compares Hims & Hers Health and SOPHiA GENETICS”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35 billion	2.40	$128.37 million	$0.51	48.51
SOPHiA GENETICS	$77.27 million	4.09	-$79.00 million	($0.51)	-9.04

Hims & Hers Health has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 13.7% of Hims & Hers Health shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Hims & Hers Health has a beta of 2.55, suggesting that its stock price is 155% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Profitability

This table compares Hims & Hers Health and SOPHiA GENETICS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	5.47%	22.48%	7.02%
SOPHiA GENETICS	-44.22%	-50.60%	-21.00%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Hims & Hers Health and SOPHiA GENETICS, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	1	13	3	0	2.12
SOPHiA GENETICS	1	0	2	0	2.33

Hims & Hers Health presently has a consensus price target of $30.75, suggesting a potential upside of 24.30%. SOPHiA GENETICS has a consensus price target of $7.00, suggesting a potential upside of 51.84%. Given SOPHiA GENETICS’s stronger consensus rating and higher probable upside, analysts plainly believe SOPHiA GENETICS is more favorable than Hims & Hers Health.

Summary

Hims & Hers Health beats SOPHiA GENETICS on 11 of the 14 factors compared between the two stocks.

About Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.